Meeting
2020 Genitourinary Cancers Symposium
Prevalence and clinical impact of BRCA1/2 mutations in patients with de novo metastatic hormone-sensitive prostate cancer (mHSPC).
Authors
Nieves Martinez Chanza
Jules Bordet Institute, Brussels, Belgium
Nieves Martinez Chanza , Marie Tkint De Roodenbeke , Laurence Desmyter , Francoise Wilkin , Cindy Badoer , Isabelle Vandernoot , Guillaume Smits , Anna Ayako Accarain , Spyridon Sideris , Thierry Gil , Ahmad Awada , Thierry Andre Roumeguere , Anis Hamid
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Patient-Reported Outcomes and Real-World Evidence
Citation
J Clin Oncol 38, 2020 (suppl 6; abstr 44)
Abstract #
44
Poster Bd #
B10
Abstract Disclosures
Similar Posters
Poster
2018 Genitourinary Cancers Symposium
Treatment patterns for metastatic hormone-sensitive prostate cancer (mHSPC) progressing after up-front docetaxel in combination with androgen deprivation therapy (D-ADT).
First Author: Pedro C. Barata
Poster
2023 ASCO Genitourinary Cancers Symposium
Prognostic value of pretreatment lung immune prognostic index in patients with metastatic hormone-sensitive and castration-resistant prostate cancer.
First Author: Zhipeng Wang
Poster
2023 ASCO Annual Meeting
Prostate-specific antigen value at 3 & 7 months (PSA-3mo, PSA-7mo) and overall survival (OS) in metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen deprivation (ADT) with or without orteronel (SWOG S1216).
First Author: Mamta Parikh
Poster
2023 ASCO Genitourinary Cancers Symposium
Survival outcomes in metastatic castration-resistant prostate cancer in the up-front treatment era.
First Author: Shunsuke Kamijo